Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. Summary
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
30.95(c) 31.05(c) 30.25(c) 30.05(c) 29.25 Last
7 389 23 587 16 797 11 157 36 146 Volume
0.00% +0.32% -2.58% -0.66% -2.66% Change
More quotes
Estimated financial data (e)
Sales 2021 99,4 M 118 M 118 M
Net income 2021 8,60 M 10,2 M 10,2 M
Net cash position 2021 50,3 M 59,6 M 59,6 M
P/E ratio 2021 38,6x
Yield 2021 -
Sales 2022 0,77 M 0,91 M 0,91 M
Net income 2022 -52,3 M -62,0 M -62,0 M
Net Debt 2022 3,15 M 3,74 M 3,74 M
P/E ratio 2022 -8,76x
Yield 2022 -
Capitalization 501 M 595 M 595 M
EV / Sales 2021 4,54x
EV / Sales 2022 658x
Nbr of Employees 27
Free-Float 71,6%
More Financials
Company
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline... 
More about the company
Ratings of ABIVAX
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ABIVAX
07/23Abivax annonce la mise à disposition d'un prospectus dans le cadre de son aug..
DJ
07/23Abivax publishes a prospectus in the context of its capital increase and bond..
DJ
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
07/23ABIVAX SOCIETE ANONYME : Prices $100 Million Capital Raise to Fund Clinical Prog..
MT
07/23ABIVAX SOCIETE ANONYME : announces the pricing of its oversubscribed capital inc..
PU
07/23PRESS RELEASE : Abivax announces the pricing of -4-
DJ
07/23PRESS RELEASE : Abivax announces the pricing of -3-
DJ
07/23PRESS RELEASE : Abivax announces the pricing of -2-
DJ
07/23PRESS RELEASE : Abivax announces the pricing of its oversubscribed capital incre..
DJ
07/23Abivax annonce le succès de son augmentation de -4-
DJ
07/23Abivax annonce le succès de son augmentation de -5-
DJ
07/23Abivax annonce le succès de son augmentation de -3-
DJ
07/23Abivax annonce le succès de son augmentation de -2-
DJ
07/23Abivax annonce le succès de son augmentation de capital sursouscrite de 60 mi..
DJ
07/23ABIVAX SOCIETE ANONYME : announces the pricing of its oversubscribed capital inc..
EQ
More news
News in other languages on ABIVAX
07/23ABIVAX : Annonce La Mise A Disposition D'un Prospectus Dans Le Cadre De Son Augm..
07/23ABIVAX : annonce la mise à disposition d'un prospectus dans le cadre de son augm..
07/23FINANCEMENTS DILUTIFS : la machine à Penny Stocks
07/23STOCK MARKET PARIS : Paris ouvre dans le vert
07/23Les valeurs à suivre aujourd'hui à la Bourse de Paris Vendredi 23 juillet 202..
More news
Chart ABIVAX
Duration : Period :
ABIVAX Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 30,05 €
Average target price 57,80 €
Spread / Average Target 92,3%
EPS Revisions
Managers and Directors
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ABIVAX-12.65%595
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907